Disappearance of Both the BCR/ABL1 Fusion Gene and the JAK2V617F Mutation with Dasatinib Therapy in a Patient with Imatinib-Resistant Chronic Myelogenous Leukemia

被引：10

作者：

Inokuchi, Koiti ^{[1
]}

Yamaguchi, Hiroki ^{[1
]}

Tamai, Hayato ^{[1
]}

Dan, Kazuo ^{[1
]}

机构：

[1] Nippon Med Sch, Dept Hematol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2012年 / 52卷 / 02期

关键词：

JAK2V617F; CML; dasatinib;

D O I：

10.3960/jslrt.52.145

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：145 / 147

页数：3

共 12 条

[1] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia [J].

de Mello Conchon, Monika Ribeiro ;

Costa, Juliana Lima ;

Yoshinaga Novaes, Mafalda Megumi ;

Dorlhiac-Llacer, Pedro Enrique ;

Fischer Chamone, Dalton de Alencar ;

Bendit, Israel .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) :243-245

[2] TRANSFORMATION OF POLYCYTHEMIA-VERA TO PH-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [J].

HAQ, AU .

AMERICAN JOURNAL OF HEMATOLOGY, 1990, 35 (02) :110-113

[3] Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation [J].

Hussein, Kais ;

Bock, Oliver ;

Seegers, Anna ;

Flasshove, Michael ;

Henneke, Felicitas ;

Buesche, Guntram ;

Kreipe, Hans Heinrich .

BLOOD, 2007, 109 (09) :4106-4107

[4] Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia [J].

Inami, M. ;

Inokuchi, K. ;

Okabe, M. ;

Kosaka, F. ;

Mitamura, Y. ;

Yamaguchi, H. ;

Dan, K. .

LEUKEMIA, 2007, 21 (05) :1103-1104

[5] Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis [J].

Jallades, Laurent ;

Hayette, Sandrine ;

Tigaud, Isabelle ;

Johnston, Anna ;

Coiffier, Bertrand ;

Magaud, Jean-Pierre ;

Ffrench, Martine .

LEUKEMIA RESEARCH, 2008, 32 (10) :1608-1610

[6] JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia [J].

Kraemer, Alwin ;

Reiter, Andreas ;

Kruth, Jens ;

Erben, Philipp ;

Hochhaus, Andreas ;

Mueller, Martin ;

Cross, Nicholas C. P. ;

Jones, Amy V. ;

Ho, Anthony D. ;

Hensel, Manfred .

LANCET ONCOLOGY, 2007, 8 (07) :658-660

[7] Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays [J].

Lombardo, LJ ;

Lee, FY ;

Chen, P ;

Norris, D ;

Barrish, JC ;

Behnia, K ;

Castaneda, S ;

Cornelius, LAM ;

Das, J ;

Doweyko, AM ;

Fairchild, C ;

Hunt, JT ;

Inigo, I ;

Johnston, K ;

Kamath, A ;

Kan, D ;

Klei, H ;

Marathe, P ;

Pang, SH ;

Peterson, R ;

Pitt, S ;

Schieven, GL ;

Schmidt, RJ ;

Tokarski, J ;

Wen, ML ;

Wityak, J ;

Borzilleri, RM .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6658-6661

[8] Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro [J].

Oehler, L ;

Jaeger, E ;

Alexander, ER ;

Sillaber, C ;

Gisslinger, H ;

Geissler, K .

BLOOD, 2003, 102 (06) :2240-2242

[9] The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders [J].

Scott, LM ;

Campbell, PJ ;

Baxter, EJ ;

Todd, T ;

Stephens, P ;

Edkins, S ;

Wooster, R ;

Stratton, MR ;

Futreal, PA ;

Green, AR .

BLOOD, 2005, 106 (08) :2920-2921

[10] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

← 1 2 →